Fibrocell Science Inc. (FCSC) financial statements (2021 and earlier)

Company profile

Business Address 405 EAGLEVIEW BOULEVARD
EXTON, PA 19341
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments141718293760
Cash and cash equivalents141718293760
Receivables   (0)00
Inventory, net of allowances, customer advances and progress billings   011
Inventory   011
Other undisclosed current assets001111
Total current assets:151818313962
Noncurrent Assets
Property, plant and equipment111222
Intangible assets, net (including goodwill)   455
Intangible assets, net (excluding goodwill)   455
Other noncurrent assets000 00
Total noncurrent assets:122667
TOTAL ASSETS:161920374669
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities222233
Accounts payable010013
Accrued liabilities112220
Deferred rent credit0
Due to related parties02111  
Deferred revenue and credits  000
Other undisclosed current liabilities  020 
Total current liabilities:2431534
Noncurrent Liabilities
Liabilities, other than long-term debt243111
Deferred revenue and credits11   
Deferred rent credit1
Other liabilities   111
Derivative instruments and hedges, liabilities132   
Other undisclosed noncurrent liabilities22661115
Total noncurrent liabilities:46971216
Total liabilities:61012231519
Stockholders' equity
Stockholders' equity attributable to parent1098143050
Common stock000000
Additional paid in capital199188170161143137
Accumulated deficit(189)(179)(163)(147)(113)(87)
Total stockholders' equity:1098143050
TOTAL LIABILITIES AND EQUITY:161920374669

Income statement (P&L) ($ in millions)

12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenues  0000
Revenue, net 0000
Cost of revenue  (1)(1)(2)(8)
Cost of goods and services sold  (1)(0)(2)(8)
Gross profit:  (0)(0)(2)(8)
Operating expenses(12)(13)(22)(22)(28)(23)
Other undisclosed operating income (loss) (6)(4)(15)11
Operating loss:(12)(19)(26)(37)(30)(31)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
  (0)00 
Interest and debt expense(1)(1)(0)  0
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes    4(1)
Loss from continuing operations before equity method investments, income taxes:(13)(20)(27)(37)(26)(32)
Other undisclosed income from continuing operations before income taxes34113  
Net loss attributable to parent:(10)(16)(15)(34)(26)(32)
Preferred stock dividends and other adjustments(0)(0)    
Other undisclosed net loss available to common stockholders, basic(1)(4)    
Net loss available to common stockholders, basic:(11)(21)(15)(34)(26)(32)
Dilutive securities, effect on basic earnings per share (0)(2)2  
Other undisclosed net loss available to common stockholders, diluted   (3)(3)(2)
Net loss available to common stockholders, diluted:(11)(21)(17)(36)(28)(34)

Comprehensive Income ($ in millions)

12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(10)(16)(15)(34)(26)(32)
Comprehensive loss, net of tax, attributable to parent:(10)(16)(15)(34)(26)(32)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: